文献速递细胞病理与分子病理泌尿与男性生殖病理

SHGUC与HGUC是否应保持为独立诊断类别

Should "suspicious for high-grade urothelial carcinoma" and "positive for high-grade urothelial carcinoma" remain separate categories?
PubMed 文献 · Cancer Cytopathol · 2020-10-09

本研究从两家大型学术机构病理数据库检索2016年1月至2019年7月诊断为SHGUC或HGUC的尿液标本,仅纳入6个月内有随访活检的病例,比较两类诊断的准确性与恶性风险(ROM)。

要点

  • SHGUC组活检证实HGUC为95/122(78%),HGUC组为64/67(96%)。
  • 两组活检证实HGUC比例差异有统计学意义(P < .001)。
  • 不一致病例多数有膀胱内卡介苗或丝裂霉素治疗史。

核心结论

  • SHGUC与HGUC的恶性风险差异在本研究队列中有统计学意义,初步提示两类TPS诊断应保持独立。

主要发现

  • SHGUC组122例中95例(78%)活检证实HGUC,HGUC组67例中64例(96%)活检证实HGUC。
  • 两组活检证实HGUC比例差异有统计学意义(P < .001)。
  • 不一致病例多数有膀胱内卡介苗或丝裂霉素治疗史。

关键数值与推荐

  • SHGUC适用于尿路上皮细胞少、异型性严重但数量不足以诊断HGUC的病例。
  • 活检证实HGUC比例:SHGUC组95/122(78%),HGUC组64/67(96%),P < .001。

临床怎么用

  • 尿细胞学报告中SHGUC与HGUC宜分别报告,不宜合并,以保留两者恶性风险的差异信息。

局限性

  • 摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Paris System (TPS) for Reporting Urinary Cytology aims to standardize urine cytology reporting. Per TPS, the diagnosis of "suspicious for high-grade urothelial carcinoma (SHGUC)" is applied in cases that have few urothelial cells with severe atypia but are quantitatively insufficient for a diagnosis of "high-grade urothelial carcinoma (HGUC)." In our study, we compared the diagnostic accuracy and risk of malignancy (ROM) of these 2 categories to assess whether they could be combined in clinical practice to perhaps improve overall interobserver variability. METHODS: All urine specimens with a diagnosis of either SHGUC or HGUC from January 2016 to July 2019 were retrieved from the pathology database of 2 large academic institutions. Only cases with follow-up biopsies within 6 months were included. RESULTS: One hundred eighty-nine cases met the study criteria. Of these, 122 had a cytologic diagnosis of SHGUC, and 67 had a diagnosis of HGUC. Ninety-five (78%) cases from the SHGUC group and 64 (96%) cases from the HGUC group had biopsy-proven HGUC. The majority of cases with discordance had a history of treatment with either intravesical bacillus Calmette-Guérin or mitomycin. The difference in the rate of biopsy-proven HGUC between the SHGUC category and the HGUC category (95/122 vs 64/67, respectively) was statistically significant (P < .001). CONCLUSIONS: The difference in ROM between SHGUC and HGUC was statistically significant in our study cohort. Intravesical chemotherapy was frequently observed in negative biopsy cases in both groups. Our preliminary findings suggest that the 2 TPS categories should remain separate.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Nguyen L, Nilforoushan N, Krane JF, et al. Should "suspicious for high-grade urothelial carcinoma" and "positive for high-grade urothelial carcinoma" remain separate categories? Cancer Cytopathol. 2020. PMID: 33036060. doi:10.1002/cncy.22357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。